AMD collaborates with Absci for AI drug discovery advancements. AMD makes a $20 million investment to boost drug research. Get access to the leaderboards pointing to tomorrow’s biggest stock movers.

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...

On January 8, AMD entered a strategic collaboration with Absci Corporation, including a $20 million investment to support the company’s AI-driven drug discovery efforts. By providing AMD ...

Absci Corporation has announced a strategic partnership with AMD to utilize AMD Instinct™ accelerators and ROCm™ software for advancing AI-driven drug discovery, specifically in de novo ...

The deal is structured as a private investment in a public equity and includes an equity stake in Absci. AMD didn’t disclose the amount of its stake.

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for ...

Absci is also collaborating with AMD to create hardware and software that will better cater to the healthcare sector and AI-based drug discovery. The company, which has approximately 160 employees and ...

Absci Corporation (ABSI) announced a strategic collaboration with AMD (AMD) to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci’s ...

$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software ...